Concert Pharma (CNCE) Reports Q3 EPS of $5.44

Concert Pharma (NASDAQ: CNCE) reported Q3 EPS of $5.44, versus ($0.51) reported last year. Revenue for the quarter came in at $143.8 million versus the consensus estimate of $11.7 thousand.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Movano (MOVE) Misses Q2 EPS by 195c